Rock Springs Capital NAMSW Position
Active8-Fund ConvergenceRock Springs Capital trimmed their position in NewAmsterdam Pharma Co N.V. (NAMSW) in Q4 2025, holding $19.5M worth of shares across 557,194 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
NAMSW is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
Full company profile →Rock Springs Capital NAMSW Position History
Frequently Asked Questions
Does Rock Springs Capital own NAMSW?
Yes. As of Q4 2025, Rock Springs Capital holds 557,194 shares of NewAmsterdam Pharma Co N.V. (NAMSW) valued at $19.5M. This data comes from their SEC 13F filing.
How many hedge funds own NAMSW?
8 specialist biotech hedge funds currently hold NAMSW, including RA Capital Management, Deerfield Management, Cormorant Asset Management and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Rock Springs Capital first buy NAMSW?
Rock Springs Capital's position in NAMSW was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Rock Springs Capital's NAMSW position increasing or decreasing?
Rock Springs Capital trimmed their NAMSW position in the most recent quarter, reducing by 38,735 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NAMSWCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Rock Springs CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →